


MDR Eudamed 1st Vigilance WG Meeting

Planning - Roadmap




Modules in Eudamed

Article 33 MDR/30 IVDR - Electronic Systems included in Eudamed





Deadlines





Deliverables

- Implementation Plan
- Functional Specifications
 - Legal requirements
 - Needs (feedback from WGs)
 - High-level requirements
 - Scope
 - Architecture overview of Eudamed
 - Actors



WG Collaboration

- Workgroup Collaboration based on:
 - Wireframes
 - Epics
 - Processes
 - Logical Data Models + Constraints
 - Roles and grants




Input from WG

- Following input is expected from the workgroup:
 - By 15/02/18: Feedback on functional specs
 - This allows COM to send consolidated Vigilance functional specs to MDCG by 23/02/18
 - 1st draft of forms asap and by 16/04
 - Field Safety Corrective Action (FSCA)
 - Periodic Summary Report (PSR)
 - Trend Report (TR)
 - Field Safety Notice (FSN)
 - Periodic Safety Update Reports (PSUR)




Planning






Planning





Overall Roadmap





Conclusion Roadmap

Planning

- Commitment of resources for timely deliveries
- Progress based on reviews of mock-up and/or prototypes
- Only 1 Audit on final release including all modules and functionalities (no partial go-live)
- Implementation Plan for functional specifications
- Acceptance testing as soon as modules / functionalities are ready
- Derogation applied as long as MDR Eudamed is not functional

Content

WG feedback should result in user-friendly functionality



Risks



Business Risks

Implementation time not respected:

- MDR Eudamed must be ready enough time before the date of application of the Regulations (deadline)
- Art 33(3) Shall give due consideration to compatibility with national systems
- Art 34 Audit requirement
- MDCG satisfaction + Needs for implementing acts (e.g. Art 33(8))

Legal basis inconsistent and/or incomplete → Implementation difficult/impossible

Purposes not met:

- unique identification and to facilitate traceability of devices within the internal market
- public adequately informed about devices placed on the market, their certificates issued by NBs, the relevant economic operators and the CI/PS
- manufacturers to comply with information obligations on vigilance and post-market surveillance
- the CAs and the EC to carry out their tasks relating to this Regulation on a well-informed basis and to enhance the cooperation between them
- Sponsors to carry out their tasks and to comply with their obligations on CI/PS
- Notified Bodies to carry out their tasks and to comply with their obligations

Workability/Traceability

- (Basic) UDI-DI Registration: Primary key in Eudamed to identify the devices in all modules → workability of Eudamed as tool for traceability
- Single Identification number for CI/PS



Business Risks

Business risks – Impact/Probability

Impact/ Probability	Probability					
		Very high	High	Medium	Low	Very low
	Very high					- Health of MD users impacted
Impact	High		Time for gathering requirements too longTime for implementation too long	- MF cannot comply to their obligations on vigilance and post- market surveillance	Audit requirement not metMDCG satisfaction not metImplementing acts not done/appropriate	
	Medium			 UDI and traceability not working (Workability) CAs and EC cannot carry out their tasks and be well informed		
	Low				- Public not adequately informed	
	Very low					



Requirements specification

 Working group members & Steering Committee together with Commission might not be able to specify the requirements in enough detail or wrongly or differently interpret the regulation which causes delay or incorrect implementation

Probability: high

Impact: high

E.g.

Specifications for PSR and TR



Requirements specification

 New requirements might appear after the functional specifications have been agreed on causing scope creep and delays or extra costs; problems to achieve a positive audit report.

Probability : High

Impact : High



Requirements specification

• Due to excessive requirements the MDR EUDAMED could become too complex and would thus not meet the needs of the national competent authorities, the economic operators and the public at large (including healthcare professionals)

Probability : Medium

Impact : High



Data integrity

- MDR Eudamed could, e.g. due to an incorrect implementation, contain corrupted data.
 - Probability: very low
 - Impact : Very High
 - thorough testing and secure development practices will lower these risks.



Disclosure of non-public data

- An incorrect implementation might result in the disclosure of confidential data or personal data to non-authorised persons
 - Probability: Low
 - Impact: Very High
 - Mitigation: exclude confidential, commercial and personal data if possible; have good authorisation and authentication



Questions?